The Frizzled 3 gene is associated with methamphetamine psychosis in the Japanese population

Behavioral and Brain Functions

Volumn 4, Issue , 2008, Pages

  Kishimoto, Makiko ^a   Ujike, Hiroshi ^a,b   Okahisa, Yuko ^a   Kotaka, Tatsuya ^a   Takaki, Manabu ^a   Kodama, Masafumi ^a   Inada, Toshiya ^b,c   Yamada, Mitsuhiko ^b,d   Uchimura, Naohisa ^b,e   Iwata, Nakao ^b,f   Sora, Ichiro ^b,g   Iyo, Masaomi ^b,h   Ozaki, Norio ^b,i   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b JGIDA ^*  (Japan)

^c SEIWA HOSPITAL   (Japan)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^e KURUME UNIVERSITY   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h CHIBA UNIVERSITY   (Japan)

ⁱ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FRIZZLED PROTEIN; FRIZZLED PROTEIN 3; METHAMPHETAMINE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; DNA FLANKING REGION; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INTRON; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 52649099483     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-4-37     Document Type: Article

References (38)

1. Bloom FE: Advancing a neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 1993, 50:224-227. 8439244
2. Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669. 3606332
3. Nusse R Varmus HE: Wnt genes. Cell 1992. 69:1073-1087. 10.1016/ 0092-8674(92)90630-U 1617723
4. Parr BA McMahon AP: Wnt genes and vertebrate development. Curr Opin Genet Dev 1994, 4:523-528. 10.1016/0959-437X(94)90067-D 7950319
5. Grove EA Tole S Limon J Yip L Ragsdale CW: The hem of the embryonic cerebral cortex is defined by the expression of multiple Wnt genes and is compromised in Gli3-deficient mice. Development 1998, 125:2315-2325. 9584130
6. Hall AC Lucas FR Salinas PC: Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 2000, 100:525-535. 10.1016/S0092-8674(00)80689-3 10721990
7. Lucas FR Salinas PC: WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Dev Biol 1997, 192:31-44. 10.1006/dbio.1997.8734 9405095
8. Cotter D Kerwin R al-Sarraji S Brion JP Chadwich A Lovestone S Anderton B Everall I: Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental abnormality. Neuroreport 1998, 9:1379-1383. 10.1097/00001756-199805110-00024 9631433
9. McMahon AP Bradley A: The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell 1990, 62:1073-1085. 10.1016/0092-8674(90)90385-R 2205396
10. Wang Y Thekdi N Smallwood PM Macke JP Nathans J: Frizzled-3 is required for the development of major fiber tracts in the rostral CNS. J Neurosci 2002, 22:8563-8573. 12351730
11. Diwadkar VA DeBellis MD Sweeney JA Pettegrew JW Keshavan MS; Abnormalities in MRI-measured signal intensity in the corpus callosum in schizophrenia. Schizophr Res 2004, 67:277-282. 10.1016/ S0920-9964(03)00098-7 14984888
12. Ananth H Popescu I Critchley HD Good CD Frackowiak RS Dolan RJ: Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry 2002, 159:1497-1505. 10.1176/ appi.ajp.159.9.1497 12202269
13. Kozlovsky N Belmaker RH Agam G: GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol 2002, 12:13-25. 10.1016/S0924-977X(01)00131-6 11788236
14. Katsu T Ujike H Nakano T Tanaka Y Nomura A Nakata K Takaki M Sakai A Uchida N Imamura T Kuroda S: The human frizzled-3 (FZD3) gene on chromosome 8p21, a receptor gene for Wnt ligands, is associated with the susceptibility to schizophrenia. Neurosci Lett 2003, 353:53-56. 10.1016/ j.neulet.2003.09.017 14642436
15. Yang J Si T Ling Y Ruan Y Han Y Wang X Zhang H Kong Q Li X Liu C Zhang D Zhou M Yu Y Liu S Shu L Ma D Wei J: Association study of the human FZD3 locus with schizophrenia. Biol Psychiatry 2003, 54:1298-1301. 10.1016/ S0006-3223(03)00291-9 14643098
16. Zhang Y Yu X Yuan Y Ling Y Ruan Y Si T Lu T Wu S Gong X Zhu Z Yang J Wang F Zhang D: Positive association of the human frizzled 3 (FZD3) gene haplotype with schizophrenia in Chinese Han population. Am J Med Genet B Neuropsychiatr Genet 2004, 129B(1):16-19. 10.1002/ajmg.b.30076 15274031
17. Hashimoto R Suzuki T Iwata N Yamanouchi Y Kitajima T Kosuga A Tatsumi M Ozaki N Kamijima K Kunugi H: Association study of the frizzled-3 (FZD3) gene with schizophrenia and mood disorders. J Neural Transm 2005, 112:303-307. 10.1007/s00702-004-0264-2 15657645
18. Ide M Muratake T Yamada K Iwayama-Shigeno Y Iwamoto K Takao H Toyota T Kaneko N Minabe Y Nakamura K Kato T Mori N Asada T Someya T Yoshikawa T: Genetic and expression analyses of FZD3 in schizophrenia. Biol Psychiatry 2004, 56:462-465. 10.1016/j.biopsych.2004.06.039 15364045
19. Wei J Hemmings GP: Lack of a genetic association between the frizzled-3 gene and schizophrenia in a British population. Neurosci Lett 2004, 366:336-338. 10.1016/j.neulet.2004.05.063 15288446
20. Sato M: A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann N Y Acad Sci 1992, 654:160-170. 10.1111/ j.1749-6632.1992.tb25965.x 1632581
21. Ujike H Sato M: Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 2004, 1025:279-287. 10.1196/annals.1316.035 15542728
22. Snyder SH: AmphetAmine psychosis: a "model" schizophrenia mediated by catecholamines. Am J Psychiatry 1973, 130:61-67. 4345465
23. Ujike H: Stimulant-induced psychosis and Tchizophrenia: the role of sensitization. Curr Psychiatry Rep 2002, 4:177-184. 10.1007/ s11920-002-0024-7 12003679
24. Kazahaya Y Akimoto K Otsuki S: Subchronic methamphetamine treatment enhances methamphetamine- or cocaine-induced dopamine efflux in vivo. Biol Psychiatry 1989, 25:903-912. 10.1016/0006-3223(89)90270-9 2720005
25. Laruelle M Abi-Dargham A van Dyck CH Gil R D'Souza CD Erdos J McCance E Rosenblatt W Fingado C Zoghbi SS Baldwin RM Seibyl JP Krystal JH Charney DS Innis RB: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996, 93:9235-9240. 38625 8799184 10.1073/pnas.93.17.9235
26. Prakash N Brodski C Naserke T Puelles E Gogoi R Hall A Panhuysen M Echevarria D Sussel L Weisenhorn DM Martinez S Arenas E Simeone A Wurst W: A Wnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. Development 2006, 133:89-98. 10.1242/dev.02181 16339193
27. Panhuysen M Vogt Weisenhorn DM Blanquet V Brodski C Heinzmann U Beisker W Wurst W; Effects of Wnt1 signaling on proliferation in the developing mid-/hindbrain region. Mol Cell Neurosci 2004, 26:101-111. 10.1016/ j.mcn.2004.01.011 15121182
28. Lovestone S Killick R Di Forti M Murray R: Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 2007, 30:142-149. 10.1016/ j.tins.2007.02.002 17324475
29. Bibb JA: Decoding dopamine signaling. Cell 2005, 122:153-155. 10.1016/ j.cell.2005.07.011 16051141
30. Emamian ES Hall D Birnbaum MJ Karayiorgou M Gogos JA: Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004, 36:131-137. 10.1038/ng1296 14745448
31. Beasley C Cotter D Khan N Pollard C Sheppard P Varndell I Lovestone S Anderton B Everall I: Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 2001, 302:117-120. 10.1016/S0304-3940(01)01688-3 11290401
32. Yang SD Yu JS Lee TT Yang CC Ni MH Yang YY: Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder. J Cell Biochem 1995, 59:108-116. 10.1002/jcb.240590112 8530529
33. Nadri C Kozlovsky N Agam G Bersudsky Y: GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res 2002, 112:51-57. 10.1016/ S0165-1781(02)00191-9 12379450
34. Proitsi P Li T Hamilton G Di Forti M Collier D Killick R Chen R Sham P Murray R Powell J Lovestone S: Positional pathway screen of wnt signaling genes in schizophrenia: Association with DKK4. Biol Psychiatry 2008, 63:13-16. 10.1016/j.biopsych.2007.03.014 17553464
35. Svenningsson P Tzavara ET Carruthers R Rachleff I Wattler S Nehls M McKinzie DL Fienberg AA Nomikos GG Greengard P: Diverse psychotomimetics act through a common signaling pathway. Science 2003, 302:1412-1415. 10.1126/science.1089681 14631045
36. Beaulieu JM Sotnikova TD Yao WD Kockeritz L Woodgett JR Gainetdinov RR Caron MG: Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004, 101:5099-5104. 387380 15044694 10.1073/pnas.0307921101
37. Kozlovsky N Amar S Belmaker RH Agam G: Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol 2006, 9:337-342. 10.1017/S1461145705006097 16191209
38. Alimohamad H Sutton L Mouyal J Rajakumar N Rushlow WJ: The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J Neurochem 2005, 95:513-525. 10.1111/j.1471-4159.2005.03388.x 16144542